Litigation Details for Scilex Pharmaceuticals, Inc. v. Aveva Drug Delivery Systems, Inc. (S.D. Fla. 2022)

Docket	⤷ Start Trial	Date Filed	2022-06-22
Court	District Court, S.D. Florida	Date Terminated	2024-08-26
Cause	35:0271 Patent Infringement	Assigned To	William P. Dimitrouleas
Jury Demand	Plaintiff	Referred To	Patrick M. Hunt
Parties	AVEVA DRUG DELIVERY SYSTEMS, INC.
Patents	10,765,640; 10,765,749; 11,278,623; 9,283,174; 9,925,264; 9,931,403
Attorneys	Robert Salvatore Visca
Firms	Brodsky Fotiu-Wojtowicz, PLLC
Link to Docket	External link to docket

The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2022-06-22				External link to document
2022-06-22	1	Complaint	expiration of U.S. Patent Nos. 9,283,174 (the “’174 patent”), 9,925,264 (the “’264 patent”), and 9,931,403… This is an action for patent infringement under the patent laws of the United States, Title…,403 (the “’403 patent”) (collectively “the Asserted Patents”). Aveva Drug Delivery Systems, Inc. notified…Asserted Patents in the event that Aveva’s ANDA Product is approved before the Asserted Patents expire… copy of the ’174 patent is attached as Exhibit A. The ’174 patent is assigned to ITOCHU	External link to document
2022-06-22	138	In Limine	Wands factors, U.S. Patent Nos. 9,283,174 (“’174 patent”), 9,925,264 (“’264 patent”), and 9,931,403….” (Ex. 5 (’174 Patent) at cl. 1; Ex. 6 (’403 Patent) at cl. 1; Ex. 7 (’264 Patent) at cl. 1.) Notably…9,931,403 (“’403 patent”) (collectively referred to as the “Asserted Patents”) are invalid for lack of enablement…and 14-16 of the ’174 patent, claims 1-4, 6-10, and 14-15 of the ’403 patent, and claims 1-4, 6-10… ’174 patent encompasses 1,111,176,000 “potential formulations.” Claim 1 of the ’174 patent recites	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document